A catalog-style entry titled “Approved Bispecific Antibodies” points to the growing set of bispecific antibody approvals in the market. While the provided content does not include specific company-level details or trial identifiers, the underlying message is that bispecifics remain an active commercial segment in regulatory outcomes. For biotech professionals, the practical takeaway is that the regulatory bar for bispecific formats continues to clear across multiple therapeutic areas, reinforcing ongoing investment in multi-specific mechanisms of action. The item is best viewed as a market reference point pending additional article details for therapeutic and sponsor specificity.